Epratuzumab for systemic lupus erythematosus

Expert Opinion on Biological Therapy

Volumn 14, Issue 7, 2014, Pages 1045-1047

  Antoniu, Sabina ^a  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

BILAG scores; Epratuzumab; Lupus; Quality of life

Indexed keywords

CORTICOSTEROID; EPRATUZUMAB; PLACEBO; MONOCLONAL ANTIBODY;

ARTICLE; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; OUTCOME ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMIC LUPUS ERYTHEMATOSUS; FEMALE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; SEVERITY OF ILLNESS INDEX;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 84902176996     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2014.915937     Document Type: Article

References (4)

1. Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011;365(22):2110-21
2. Trials C. Study of Epratuzumab versus placebo in subjects with moderate to severe general systemic lupus erythematosus (EMBODY 1). 2014. Available from: http://www. clinicaltrials.gov/ct2/show/NCT01262365?term=embody&rank=1
3. Strand V, Petri M, Kalunian K, et al. Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. Rheumatology (Oxford) 2014;53(3):502-11
4. Wallace DJ, Gordon C, Strand V, et al. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology (Oxford) 2013;52(7):1313-22